Showing results (131-140 of 178) with videos related to

Sort By:
Pageof 18
Psychopharmacology Bulletin|August 23, 2021
Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a PrimerSagar V Parikh, Daniela Lopez, Jennifer L Vande Voort, et al.
Journal of Psychiatric Research|April 5, 2026
The association between body mass index and treatment outcomes in major depressive disorder: a CAN-BIND-1 studyHelena K Kim, Brett D M Jones, Margaret K Hahn, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|April 5, 2014
Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genesAbdul Noor, Anath C Lionel, Sarah Cohen-Woods, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 4, 2016
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsSidney H Kennedy, Raymond W Lam, Roger S McIntyre, et al.
Journal of Affective Disorders|January 24, 2020
Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkersStephen Daniels, Thomas Horman, Thomas Lapointe, et al.
Psychiatry Research|December 25, 2021
Evaluating the perceived utility of an artificial intelligence-powered clinical decision support system for depression treatment using a simulation centerMyriam Tanguay-Sela, David Benrimoh, Christina Popescu, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 26, 2025
Modulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l'étude CAN-BIND-1Chloé Stengel, Benjamin Schwartzmann, Raaj Chatterjee, et al.
Bipolar Disorders|December 15, 2012
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|January 15, 2022
Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression StudyPrabhjot Dhami, Lena C Quilty, Benjamin Schwartzmann, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 11, 2020
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif MajeurJennifer Swainson, Alexander McGirr, Pierre Blier, et al.
Pageof 18